In vivo Reprogramming of Cancer Metabolism by MYC by Roman Camarda et al.
REVIEW
published: 11 April 2017
doi: 10.3389/fcell.2017.00035
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 April 2017 | Volume 5 | Article 35
Edited by:
Victor Javier Sanchez-Arevalo Lobo,
Spanish National Cancer Research
Centre, Spain
Reviewed by:
Chi Van Dang,
University of Pennsylvania, USA
Patricia Sancho,
Queen Mary University of London, UK
*Correspondence:
Andrei Goga
andrei.goga@ucsf.edu
Specialty section:
This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 16 February 2017
Accepted: 23 March 2017
Published: 11 April 2017
Citation:
Camarda R, Williams J and Goga A
(2017) In vivo Reprogramming of
Cancer Metabolism by MYC.
Front. Cell Dev. Biol. 5:35.
doi: 10.3389/fcell.2017.00035
In vivo Reprogramming of Cancer
Metabolism by MYC
Roman Camarda 1, 2, Jeremy Williams 2 and Andrei Goga 1, 3, 4*
1Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA, 2 Biomedical
Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA, 3Department of Medicine,
University of California, San Francisco, San Francisco, CA, USA, 4Helen Diller Family Comprehensive Cancer Center,
University of California, San Francisco, San Francisco, CA, USA
The past few decades have welcomed tremendous advancements toward
understanding the functional significance of altered metabolism during tumorigenesis.
However, many conclusions drawn from studies of cancer cells in a dish (i.e., in
vitro) have been put into question as multiple lines of evidence have demonstrated
that the metabolism of cells can differ significantly from that of primary tumors (in
vivo). This realization, along with the need to identify tissue-specific vulnerabilities of
driver oncogenes, has led to an increased focus on oncogene-dependent metabolic
programming in vivo. The oncogene c-MYC (MYC) is overexpressed in a wide variety
of human cancers, and while its ability to alter cellular metabolism is well-established,
translating the metabolic requirements, and vulnerabilities of MYC-driven cancers to
the clinic has been hindered by disparate findings from in vitro and in vivo models. This
review will provide an overview of the in vivo strategies, mechanisms, and conclusions
generated thus far by studying MYC’s regulation of metabolism in various cancer
models.
Keywords: MYC, metabolism, fatty acid oxidation, glutamine, glucose, transgenic cancer models, therapeutic
irrigation, ras proteins
INTRODUCTION
Cancer is a disease of uncontrolled growth, and proliferating cells change their metabolic demands
compared to quiescent cells (DeBerardinis et al., 2008; Vander Heiden et al., 2009). Tumor cells can
outcompete normal cells, regardless of the proliferative capacity of the tissue of origin. Dysregulated
metabolism is a hallmark of tumorigenesis (Hanahan and Weinberg, 2011), and such altered
metabolism permits tumor cells to survive and proliferate despite adverse conditions.
Historical studies of altered metabolism in cancer pointed to increased glycolysis, and later
glutaminolysis, as defining characteristic of tumor cells. Significant progress has been made
studying glycolysis and glutaminolysis, and therapeutic targeting of these pathways is actively being
pursued in the clinic (Altman et al., 2016; Hay, 2016). However, it has become increasingly apparent
that while glycolysis and glutaminolysis certainly play major roles in some tumors (Hay, 2016;
Altman et al., 2016), alternative sources of “fuel” can be just as, if not more, important (Cairns and
Mak, 2016). Notably, targeting of alternative metabolic pathways, for example lipid biosynthesis,
is currently in clinical trials against a variety of tumor types, and cannot be undervalued (Galluzzi
et al., 2013).
A critical link between understanding cancer metabolism and targeting it therapeutically is
identifying the upstream effectors that reshape tumor metabolism. The proto-oncogene MYC is
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a pleiotropic transcription factor and is one of the most
commonly amplified or overexpressed genes in human cancers
(Meyer and Penn, 2008). While MYC expression is dysregulated
in a wide variety of cancers, it’s oncogenic role has most
thoroughly been studied in vivo in the context of transgenic
models of aggressive breast, liver, lung, prostate, and kidney
cancers, as well as neuroblastoma and lymphoma (see references
below; Figure 1 and Table 1). For example, we and others have
demonstrated that MYC expression is elevated in the estrogen,
progesterone and human epidermal growth factor receptor-
2 (HER2), receptor triple-negative subtype of breast cancer
(TNBC; Horiuchi et al., 2012; Koboldt et al., 2012). Additionally,
MYC translocation to the IgG locus plays a causal role in Burkitt’s
Lymphoma (Meyer and Penn, 2008; Eberlin et al., 2014). As
a transcription factor, MYC’s primary mode of transformation
is through the pro-tumorigenic transcriptional dysregulation of
a wide variety of processes including proliferation, cell size,
apoptosis, and metabolism (Meyer and Penn, 2008). Regulation
of MYC’s transcriptional activity (Kress et al., 2015), and the
role of MYC’s transcriptional binding partners in the regulation
of metabolism (Sloan and Ayer, 2010) have been studied and
reviewed, and will not be discussed here. It is also important to
note that given the broadly important role of MYC in cancer, a
direct MYC inhibitor could be of great clinical utility. However,
such an inhibitor has yet to be created, and the strategy of
targeting MYC directly remains challenging (Lockwood et al.,
2012; McKeown and Bradner, 2014). Thus, alternative strategies
of targeting MYC-driven cancers via selective inhibition of
cellular pathways, like metabolism, that may selectively kill
MYC-overexpressing cells have attractive therapeutic potential.
Indeed, the concept of specifically targetingmetabolism to induce
synthetic lethality in aMYC-dependentmanner was pioneered by
Shim et al. (1997), and expanded upon by many others (Yuneva
et al., 2007; Dang, 2011).
The ability of MYC to dynamically regulate cellular
metabolism in cancer is well-established (Wahlström and
Henriksson, 2015; Stine et al., 2015). However, it is important to
note that many studies describing MYC’s ability to reprogram
tumor cell metabolism have been conducted in vitro, primarily
using inducible/repressible transgenic and human cancer cell line
models (Wahlström and Henriksson, 2015; Stine et al., 2015).
While the importance and utility of in vitro cell culture models
is undeniable, results from these models must be considered
with caution when studying a process such as metabolism that
is dependent on tumor cell environment (Mayers and Vander
Heiden, 2015). Further, the dynamic nature of metabolic stressors
and plasticity in vivo is difficult to model in vitro, particularly
en masse. Primary tumors develop to form a complex tissue
that is exposed to varying levels of oxygenation, and fluctuating
concentrations of glucose, glutamine, amino acids and countless
other metabolites that cannot be readily modeled in tissue culture
(Mayers and Vander Heiden, 2015). Recent studies have also
revealed an intimate connection between circadian rhythms and
tissue-specific metabolism that has yet to be fully considered in
the context of cancer metabolism (Abbondante et al., 2016). This
last point is particularly prescient given the recent demonstration
by Altman et al. that MYC itself can dysregulate circadian gene
expression and metabolism (Altman et al., 2015), however, these
findings have yet to be validated in vivo.
The disparate nature of in vitro and in vivo metabolism
is exemplified by a recent study that took advantage of two
transgenic mouse models of KRAS-driven non-small cell lung
cancer (NSCLC; Davidson et al., 2016). Davidson et al. found that
both models displayed increased utilization of glucose-derived
carbon to fuel the tricarboxylic acid (TCA) cycle compared to
normal lung in vivo, while neither tumor nor non-tumor utilized
glutamine-derived carbon for the TCA cycle to a large extent.
This is in stark contrast to a cell line derived from one of
the transgenic models, which in vitro decreases its utilization
of glucose for the TCA cycle and increases its utilization of
glutamine to that end (Davidson et al., 2016). Thus, glutamine
oxidation in this model system appears to be an artifact of the in
vitro culture methods and is not observed in vivo. Such results
thus raise doubt about the utility of targeting the glutamine
pathway as a therapeutic target for primary KRAS-driven lung
tumors.
Given the dynamic nature of MYC’s function in diverse
cellular contexts, and the potential for cell culture to confound
our understanding of tumor metabolism, the goal of this review
is to focus on the regulation of cancer metabolism by MYC
in vivo. To clarify, our definition of in vivo refers to studies
of metabolism with findings based on de novo MYC-driven
tumorigenesis, usually in the form of transgenic mouse models.
While we acknowledge that many findings from in vitro studies
of MYC-driven cancer metabolism hold true in vivo (Wahlström
and Henriksson, 2015; Stine et al., 2015), we will discuss here the
various models used to study the regulation of cancer metabolism
by MYC in vivo (summarized in Table 1), and provide broader
context on some of the questions that remain to be answered.
USE OF TRANSGENIC MOUSE MODELS
AND CONSIDERATION OF
TISSUE-SPECIFIC EFFECTS
The study of cancer metabolism in vivo is of course limited
by the methods and unique challenges and considerations
that the metabolism of complex tissues warrants (Mayers and
Vander Heiden, 2015). One particularly important consideration
is the difference between “snap-shot” strategies of studying
metabolism vs. kinetic flux analyses, and how the use of
chemically labeled metabolites factors into both approaches. The
most common snap-shot method for studying metabolism is
mass spectrometry-based metabolomics, which can be “targeted”
for known metabolites or “untargeted” for unbiased detection of
all metabolites present within a particular sample, and does not
require any labeled metabolite (Medina-Cleghorn and Nomura,
2014). A second snap-shot strategy is 13C tracer analysis, in which
a 13C-labeled metabolite is infused or fed to the subject, and
mass spectrometry is used to identify downstream metabolite
labeling patterns (Buescher et al., 2015). The use of 13C-labeled
metabolites shifts from a snap-shot tracing study to a formal
kinetic flux analysis when a much more complex series of
considerations (metabolite uptake and secretion, as well as the
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FIGURE 1 | A summary of the metabolic alterations found in each MYC-driven cancer type by tissue of origin. Boxes surrounding each cancer indication
are color-coded to match the tissue of origin. HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; PDAC, pancreatic
ductal adenocarcinoma; PIN, prostatic intraepithelial neoplasia; TNBC, triple-negative breast cancer.
kinetics of the biochemical reaction network to be probed)
are taken into account (Buescher et al., 2015). A common
approach to achieve flux analysis is with constant infusion of
an isotopically labeled tracer, 13C-glucose for example, that will
achieve isotopic steady state as 13C enrichment becomes stable
over time (Buescher et al., 2015). Understanding the differences
between these methods, and the conclusions that can be drawn
from them, is vital. In particular, snap-shot metabolomics is
often used to prematurely draw conclusions about the activity
of a metabolic pathway, when the elevation or decrease of
a particular metabolite does not necessarily reflect activation
or inhibition of an entire pathway (Medina-Cleghorn and
Nomura, 2014; Buescher et al., 2015). Moreover, interpretation
and validation of metabolic data is critical, as for example,
accumulation of a particular metabolite could have multiple
potential interpretations (i.e., increased activity of an upstream
anabolic pathway or decreased activity of a downstream catabolic
pathway). An important caveat to the study of in vivometabolism
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 April 2017 | Volume 5 | Article 35
Camarda et al. In vivo Reprogramming of Cancer Metabolism by MYC
TABLE 1 | In vivo transgenic models of MYC-driven cancer (excluding hydrodynamic models).
Tissue/cancer specificity Model MYC-dependent metabolic pathways altered
Liver—HCC LAP-tTA/TRE-MYC Glycolysis (Medina-Cleghorn and Nomura, 2014; Buescher et al., 2015), glutaminolysis
(Buescher et al., 2015), glutathione biosynthesis (Altman et al., 2015), lipid metabolism
(Bott et al., 2015)
Lung—NSCLC SPC-rtTA/TRE-MYC Glycolysis (Buescher et al., 2015)
Kidney—RCC GGT-tTA/TRE-MYC Glycolysis (Anderton et al., 2017), glutaminolysis (Anderton et al., 2017)
Pancreatic—PDAC Pdx1-Cre/LSL-KRASG12D/R26-LSL-MYC Glutaminolysis (Calvisi and Thorgeirsson, 2005)
Prostate—PIN Pbsn-MYC Glycolysis (Hu et al., 2011), lipid metabolism (Hu et al., 2011)
Neural crest—NB TH-MYCN Glutathione biosynthesis (Allen et al., 2011)
Lymphocytes—BL Eµ-tTA/TRE-MYC Lipid metabolism (Eberlin et al., 2014)
Eµ-MYC/RPL24+/− Protein metabolism (D’Cruz et al., 2001), nucleotide metabolism (Pfefferle et al., 2013)
Breast—TNBC MMTV-rtTA/TRE-MYC Fatty acid oxidation (Carter et al., 2016)
A summary of the transgenic mouse models used thus far to study MYC-driven cancer metabolism in vivo. The tissue of origin, specific transgenes and primary altered metabolic
pathway(s) studied in each model are noted. References for the models can be found in the main text. HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; RCC, renal
cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; PIN, prostatic intraepithelial neoplasia; NB, neuroblastoma; BL, Burkitt’s lymphoma; TNBC, triple-negative breast cancer.
is that tumor tissue is often analyzed at a bulk level, and as
the work of Aran et al. and many others has demonstrated, the
composition of solid tumors includes a number of different cell
types (Aran et al., 2015) whose metabolism is rarely accounted
for in such bulk analyses.
With a cadre of strategies in hand, the study of cancer
metabolism in vivo then becomes a function of the models
or the clinical samples available for analysis. In this section,
we will address some of the most thoroughly used models to
study the metabolism of MYC-driven cancer (Table 1). The
overall message is that while MYC-driven metabolism during
tumorigenesis is quite tissue-specific, some shared pathways also
emerge (Figure 1).
MYC DYSREGULATES GLUCOSE AND
GLUTAMINE METABOLISM
In hepatocellular carcinoma (HCC), MYC is found to be
frequently amplified and/or overexpressed, and is associated
with poorly differentiated tumors and poor prognosis (Shachaf
et al., 2004; Calvisi and Thorgeirsson, 2005; Kaposi-Novak et al.,
2009; Lim et al., 2014; Anderton et al., 2017). In addition,
MYC expression is commonly found to be upregulated in
hepatoblastoma (HB), a liver tumor type that predominates in
pediatric patients (Wang et al., 2016).
To study MYC-dependent metabolism in HCC, we and
others have utilized the MYC-driven LAP-tTA/TRE-MYC
(LT2-MYC) transgenic mouse model of liver cancer initially
developed in the lab of J.M. Bishop, which allows for
MYC overexpression specifically in hepatocytes in the absence
of doxycycline (Shachaf et al., 2004). Importantly, mRNA
expression analysis reveals that LT2-MYC tumors effectively
model poorly differentiated, aggressive liver cancer (Lim
et al., 2014). Using this model, we probed for changes
in glycolytic metabolism using hyperpolarized 13C-pyruvate
magnetic resonance spectroscopic imaging (MRSI) during de
novo tumorigenesis and inducible tumor regression. More
specifically, hyperpolarized 13C-pyruvate MRSI allows for in vivo
flux analysis of pyruvate to lactate and/or alanine conversion.
With this modality, we found that MYC induction led to
increased pyruvate to alanine conversion in the liver that
preceded overt tumor formation, while full-blown tumors
displayed increased pyruvate to lactate conversion. Both of
these phenotypes were reversed during tumor regression.
Mechanistically, mRNA expression analysis revealed coordinate
changes in the levels of TCA cycle and glycolytic enzymes that
supported the observed metabolic changes. In particular, there
was a specific elevation of glutamate pyruvate transaminase 1,
which converts pyruvate to alanine, in pre-tumorigenic liver,
while lactate dehydrogenase A (LDHA), which converts pyruvate
to lactate, was specifically upregulated in tumors (Hu et al.,
2011). Studies such as this indicate that imaging of downstream
glycolysis pathway events can identify the earliest stages of tumor
formation and regression and that these metabolic changes are
indeed MYC dependent.
The notion that MYC drives increased glycolysis in liver
cancer was further bolstered by a parallel study of MYC-
driven metabolism using the same LT2-MYC model. Yuneva
et al. utilized a combination of steady-state profiling techniques
including nuclear magnetic resonance spectroscopy with or
without 13C-glucose and 13C-glutamine labeling, as well as 18F-
fluorodeoxyglucose positron emission tomography and mass
spectrometry (Yuneva et al., 2012). The authors found that
MYC-driven liver tumors displayed increased glucose uptake
and catabolism to lactate and TCA cycle intermediates, as
well as increased glutamine catabolism to support the TCA
cycle. These findings were supported by increased expression
of LDHA, hexokinase 2 (Hk2), and glutaminase 1 (Gls1),
and decreased expression of glutamine synthetase (Glul). The
importance of glutamine catabolism in MYC-driven HCC was
further demonstrated by Xiang et al. who demonstrated that
genetic ablation of one copy of Gls1 or treatment with two
different inhibitors of Gls1 could significantly prolong survival in
this samemodel (Xiang et al., 2015). This was in direct contrast to
glucose and glutamine utilization in transgenic MYC-driven lung
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 April 2017 | Volume 5 | Article 35
Camarda et al. In vivo Reprogramming of Cancer Metabolism by MYC
tumors (Wang et al., 2001; Allen et al., 2011). UnlikeMYC-driven
liver tumors, MYC-driven lung tumors displayed elevated lactate
and glutamine levels, which was suggestive of increased glucose
catabolism, but not glutamine catabolism. MYC-driven lung
tumors displayed increased LDHA, Hk2, Gls1 as well as Glul.
Likewise, a similar model of transgenic MYC-driven lung cancer
displayed increased LDHA and Hk2, as well as enzymes from
several other metabolic pathways, at the mRNA level (Ciribilli
et al., 2016).
Although MYC pathway activation is elevated in the majority
of renal cell carcinoma (RCC) cases, a formal study of MYC’s
role in the pathogenesis and the metabolism of RCC had been
lacking. To study MYC in RCC, Shroff et al. created an inducible
transgenic model of renal cell carcinoma (GGT-tTA/TRE-MYC)
in which MYC is specifically overexpressed in the kidney in the
absence of doxycycline (Shroff et al., 2015). Using desorption
electrospray ionization mass spectrometry imaging (DESI-MSI),
the authors studied the metabolic profiles of non-tumor kidney,
MYC-driven kidney tumors at 2 and 4 weeks post-MYC
induction, and regressed tumors after 4 weeks of switching MYC
off. The authors noted multiple metabolic changes, including in
the relative abundance of a variety of long-chain fatty acids in
tumors compared to non-tumor kidneys and regressed tumors.
Schroff and colleagues focused on glutamine metabolism after
mRNA expression analysis revealed a downregulation in many
glycolytic genes, but an upregulation in genes associated with
glutaminolysis. The authors confirmed that glutamate and TCA
cycle intermediates were elevated in tumors using DESI-MSI, and
found that their transgenic tumors, as well as MYChigh human
RCC, stained positively for Gls1 andGls2, suggesting an elevation
in glutaminolysis. Decreased staining of the transgenic tumors
for Hk1 and LDHA further supported diminished glycolysis.
Finally, the authors found that pharmacological inhibition of
Gls1 with bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl
sulfide (BPTES) abrogated the growth of MYC-driven kidney
tumors (Shroff et al., 2015), implicating glutamine utilization
as critical for MYC-driven RCCs, similar to what was found in
MYC-driven HCC (Xiang et al., 2015).
Additional evidence that MYC dysregulates glutamine
metabolism was provided by a recent study that found elevation
of the glutamine synthetase (Glul) enzyme and glutamine
abundance in a transgenic mouse model of dual MYC and
KRAS-driven pancreatic cancer, compared to tumors driven by
KRAS alone (Bott et al., 2015). These studies suggested Glul
is induced by MYC. Further support that MYC dysregulates
glucose metabolism was provided when mass spectrometry-
based metabolomic analysis was used to compare the metabolic
profiles of established transgenic mouse models of MYC-
or AKT-driven prostate cancer (Ellwood-Yen et al., 2003;
Majumder et al., 2003), as well as human prostate cancer samples
that had been profiled for activated phospho-AKT and MYC
levels. The authors found coordinately decreases in glucose-
related metabolites and downregulation of HK2 and the glucose
transporter GLUT-1 in mouse and human prostate tumors that
were MYChigh, compared to control tissue and AKThigh tumors.
In addition, the authors found specific dysregulation of several
long-chain fatty acids in MYChigh tumors, but the functional
significance of these changes was not addressed (Priolo et al.,
2014).
In summary, the ability of MYC to alter glucose and glutamine
metabolism in cancer is clear. However, the studies of MYC-
driven liver, lung, kidney, pancreatic, and prostate cancers
studied above highlight the fact that MYC can up- or down-
regulate either or both of these pathways depending on tissue
context. Furthermore, Shroff et al. were the only group to
formally demonstrate that dysregulation of one of these pathways
leads to a reliance upon it that may have therapeutic potential
(Shroff et al., 2015). Further, studies in the remaining cancer
types discussed above will be necessary to determine if targeting
glucose or glutamine metabolism will have therapeutic utility.
MYC REGULATES DOWNSTREAM
GLUTAMINE UTILIZATION
Although the LT2-MYC model had multiple changes in glucose
and glutamine metabolism (Hu et al., 2011; Yuneva et al., 2012),
other metabolic pathways had not been fully explored. Using the
conditional MYC-driven liver cancer model we conducted global
mRNA expression and mass spectrometry-based metabolomic
analyses on LT2-MYC tumors vs. control uninduced transgenic
livers (Anderton et al., 2017). Using an integrated bioinformatics
approach, we probed for metabolic pathways coordinately
dysregulated in both transcript and metabolite levels. Of
the six pathways identified: glutathione metabolism; glycine,
serine, and threoninemetabolism; aminoacyl-tRNA biosynthesis;
cysteine and methionine metabolism; ABC transporters; and
mineral absorption, we focused on glutathione metabolism
(Anderton et al., 2017). We found a marked decrease in
the reduced and oxidized form of glutathione, as well as
the enzyme responsible for de novo glutathione biosynthesis,
glutamate-cysteine ligase, catalytic subunit (GCLC). Because
glutathione is synthesized downstream of glutamine conversion
to glutamate, we performed mass spectrometry-based tracing
analysis with 13C-glutamine in a somatic transgenic model
of MYC-driven liver cancer (Tward et al., 2005). We found
that glutamine-derived carbons preferentially fueled the TCA
cycle vs. glutathione production in MYC-driven liver tumors
compared to control liver tissue. Mechanistically, we found
that GCLC expression was downregulated by miR-18a in
a MYC-dependent manner. Treatment of LT2-MYC tumor-
bearing mice with a locked-nucleic acid antagonist of miR-
18a significantly rescued GCLC expression and glutathione
levels in vivo. In addition, miR-18a was significantly elevated
in human HCC compared to non-tumor liver, was negatively
correlated with GCLC expression in human HCC, and was
positively correlated with alpha-fetoprotein (AFP) expression,
which is associated with aggressive liver cancer. Finally, we
found that LT2-MYC tumors displayed increased sensitivity to
an oxidative stress inducer, diquat, compared to non-tumor
liver. In particular, diquat-treated tumors displayed a specific
and significant increase in cell loss, TUNEL staining as a
marker of apoptosis, and decreased MYC expression (Anderton
et al., 2017). Notably, it had been previously demonstrated
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in vitro that MYC-dependent suppression of miR-23a/b results
in increased Gls1 and glutaminolysis activity (Gao et al., 2009;
Kota et al., 2009). Thus, MYC can alter the expression of
specific miRNAs (i.e., miR18a and miR23a) which in turn
regulate glutamine metabolism. MYC-dependent regulation of
miRNAs may be a common mechanism through which MYC
reprograms tumor metabolism (Figure 2) and deserves broader
consideration beyond HCC.
In neuroblastoma, the MYC-related transcription factor
MYCN is found to be amplified in∼20% of neuroblastomas, and
its amplification is associated with poor prognosis (Carter et al.,
2016). To study the role of MYCN in neuroblastoma metabolism,
Carter et al. utilized the TH-MYCN transgenic model of MYCN-
driven neuroblastoma in which MYCN is overexpressed in
cells of the neural crest (Weiss et al., 1997). Using mass
spectrometry-based metabolomics, the authors performed global
metabolic profiling of MYCN-driven neuroblastoma at multiple
time-points representing hyperplastic ganglia, early tumors, and
advanced tumors. Grouping the metabolomic data into pathway
analysis, it was found that glutathione metabolism was the
most significantly dysregulated pathway, with all metabolites
associated with glutathione biosynthesis elevated in MYCN-
driven tumors compared to control ganglia. Interestingly, the
majority of enzymes associated with glutathione biosynthesis,
including GCLC, were found to be downregulated at the mRNA
level. Therefore, the authors speculated that increased protein
biosynthesis, which was evidenced by a significant increase in the
expression of ribosome biogenesis genes, was responsible for the
observed increase in glutathione, although this contention was
not formally tested. Regardless, the increase in glutathione led the
authors to hypothesize that MYCN-driven neuroblastoma could
have an increased dependence upon glutathione metabolism.
Indeed, the authors found that BSO, an inhibitor of GCLC,
could reduce sympathetic ganglia hyperplasia and delay tumor
onset when given prophylactically. In addition, GCLC inhibitors
did not have an effect on the growth of established tumors
when given alone, but did have a significant benefit when given
with the clinically relevant chemotherapeutic agent vincristine,
compared to BSO alone or vincristine alone (Carter et al., 2016).
Thus, in both MYC driven liver and neuroblastoma models
GCLC expression is suppressed, though the effects on glutathione
production appear to be contextually dependent. We postulate
that in the setting of low GCLC expression, and consequently
lowGSH production that someMYC-driven tumors, such as liver
cancers, may be especially sensitive to exogenous oxidative stress
(Anderton et al., 2017).
Terunuma et al. conducted mass spectrometry-based
metabolomics on primary breast cancer samples and adjacent
non-tumor tissue (Terunuma et al., 2014). The authors found
a number of differences in metabolite abundance between
tumor and non-tumor samples, and probed further into the
differences between ER-positive and ER-negative tumors as well
as tumors from individuals with African ancestry vs. European
ancestry. The authors chose to focus on 2-hydroxyglutarate
(2-HG), a known “oncometabolite,” which was found to be
preferentially elevated in ER-negative tumors. Interestingly,
2-HG accumulation normally occurs in the context of isocitrate
dehydrogenase (IDH) 1 or 2 mutation, but the authors did
not find evidence of IDH mutation in breast cancer. It was
recently demonstrated that 2-HG can be produced via LDHA
in the context of hypoxia (Intlekofer et al., 2015; Oldham
et al., 2015), but Terunuma et al. did not address whether
hyoxia could explain 2-HG production in the breast tumors
analyzed. However, they did find a strong correlation between
2-HG levels, MYC pathway activity, glutaminolysis-associated
metabolites, and Gls1 expression. Further, the authors provided
in vitro evidence that 2-HG production occurs during glutamine
catabolism, and that MYC is both necessary and sufficient for
elevated 2-HG levels (Terunuma et al., 2014) in breast cell lines.
These data suggest that MYC, albeit via a yet unclear mechanism,
is able to promote glutamine utilization for 2-HG production in
cancer. It is of course tempting to speculate that MYC-dependent
regulation of LDHA, as discussed above, may contribute to the
2-HG production observed, but this remains to be determined.
In summary, MYC’s regulation of glutamine metabolism is
extensive. In the case of glutathione, relative decreases (Anderton
et al., 2017) and increases (Carter et al., 2016) were observed
depending on the cancer type. With a decrease, tumors were
found to be sensitive to an inducer of oxidative stress (Anderton
et al., 2017), while an increase led the tumors to be sensitive
to GCLC inhibition during the early phase of tumor formation
(Carter et al., 2016). Interestingly, in neuroblastoma the elevation
of glutathione occurred despite a downregulation in GCLC
mRNA levels. It would be interesting to determine if the decrease
in GCLC observed in neuroblastoma is miR-18a-dependent. An
alternative downstream use of glutamine to generate 2-HG has
also been postulated in primary breast cancers. It remains unclear
how MYC activity could induce 2-HG production, thus the
therapeutic utility and potential to target this pathway have not
been explored (Terunuma et al., 2014).
MYC DYSREGULATES LIPID METABOLISM
The role of MYC in HB metabolism has not been studied
as extensively as HCC (Cairo et al., 2008), but it is worth
noting that a recent study performed global mRNA expression
analysis in a somatic transgenic model of β-catenin/YAP-driven
HB performed in mice with either MYC-wildtype (WT) or
MYC-knockout (KO) hepatocytes. The authors found that MYC
promoted tumor progression, but not initiation, and were able
to identify several metabolic pathways with differential enzyme
expression and pathway activity in MYC-WT vs. MYC-KO
tumors (Wang et al., 2016). For example, MYC-KO tumors
displayed reduced expression of the fatty acid transporter CD36,
with a concomitant decrease in lipid droplet levels and fatty acid
oxidation (FAO; Wang et al., 2016). Given these results in HB,
it would be interesting to determine if MYC also dysregulated
lipid metabolism in HCC. To that end, Perry et al. utilized DESI-
MSI to not only detect differential abundance of lipid species
in non-tumor liver, early LT2-MYC tumors, late tumors, and
regressed tumors, but also generate a spatial localization of the
detected lipids with∼200 µm resolution (Perry et al., 2013). The
authors found that a number of lipid species displayed differential
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FIGURE 2 | MYC-dependent miRNA regulation of glutamine
metabolism. MYC was found to downregulate miR-23a/b, which targets Gls,
resulting in increased production of glutamate from glutamine (Gao et al.,
2009). In addition, MYC was found to upregulate miR-18a, which targets
GCLC, resulting in decreased production of glutathione from glutamate, and
increased flow of glutamine-derived carbon into the TCA cycle (Anderton et al.,
2017). Gray lines indicate a decreased effect, and dotted lines indicate a
multi-step metabolic pathway.
abundance in tumor vs. non-tumor tissue, but did not pursue the
functional significance of these changes.
The work of Perry et al. in MYC-driven liver cancer later
led the same lab to use DESI-MSI to study MYC-driven
lymphoma. MYC is known to be broadly dysregulated in
aggressive lymphomas, and in Burkitt’s lymphoma the MYC gene
is translocated next to the immunoglobulin heavy chain enhancer
in virtually all cases (Meyer and Penn, 2008; Eberlin et al.,
2014). To study MYC-driven lymphoma Eberlin et al. utilized
the conditional Eµ-tTA/TRE-MYC transgenic mouse model in
which MYC is specifically expressed in lymphocytes only in
the absence of doxycycline (Felsher and Bishop, 1999). The
authors reported a number of lipids that displayed differential
abundance in MYC-driven lymphoma compared to control non-
tumor thymus. In addition, the authors performed DESI-MSI on
15 human lymphoma samples, including five cases of Burkitt’s
lymphoma, that were profiled for MYC expression such that
they were classified as MYChigh or MYClow. Interestingly, there
were many similarities between the lipid profiles of the mouse
MYC-driven lymphomas and the human MYChigh lymphomas,
and both were distinct from the human MYClow lymphomas
(Eberlin et al., 2014). In addition, some of the most differentially
increased lipids in MYC-driven lymphomas were multiple
cardiolipin species, which are known to play critical roles in
mitochondrial membrane integrity. Thus, although Eberlin et al.
did not pursue the functional significance of dysregulated lipid
metabolism, these changes could support alternative aspects
of MYC-driven metabolism in lymphoma. Additionally, it is
interesting that Eberlin et al acknowledge in their discussion a
potential relationship between altered lipid abundance and FAO,
and a separate study indeed found that inhibition of FAO was
able to significantly delay tumorigenesis in a constitutive model
of transgenic MYC-driven lymphoma (Eµ-MYC; Harris et al.,
1988; Pacilli et al., 2013).
As mentioned above, we and others have demonstrated
that MYC expression is disproportionately elevated in TNBC
compared to receptor-positive (RP) tumors (Horiuchi et al.,
2012; Koboldt et al., 2012). Thus, we were particularly interested
in the use of the MYC-driven MMTV-rtTA/TRE-MYC (MTB-
TOM) transgenic mouse model of breast cancer, in which
MYC is overexpressed specifically in mammary epithelial cells
in a doxycycline-inducible manner (D’Cruz et al., 2001). It is
important to note that while MYC is certainly overexpressed
in this model, which mimics the clinically observed increase
in MYC expression in TNBC, it was also confirmed by
unbiased clustering of mRNA expression analysis that the MTB-
TOM model does resemble the Basal/TN subtype of breast
cancer (Pfefferle et al., 2013). Using this model, we performed
steady-state metabolomics and 13C-tracing analysis and found
that FAO was dysregulated. We then used a 14C-oleic acid
oxidation assay to confirm that FAO was elevated specifically
in MYC-overexpressing TNBC. Given the elevation in FAO, a
pathway known to fuel the TCA cycle and ATP production, we
hypothesized this pathway could be required to fuel bioenergetic
metabolism in MYC-overexpressing TNBC, and could have
therapeutic potential. To address this hypothesis in a more
clinically relevant model, we utilized a recently described panel
of breast cancer patient-derived xenografts (PDX; DeRose et al.,
2011). Using a specific inhibitor of the FAO pathway, etomoxir,
we found that inhibition of FAO decreased bioenergetic
metabolism and inhibited tumorigenesis in a MYChigh TN PDX,
but did not inhibit tumorigenesis in a MYClow TN PDX model
(Camarda et al., 2016). Notably, a separate study found elevated
FAO in TNBC, and described an additional downstream role for
FAO in promoting autophosphorylation and activation of the
oncogenic Src kinase (Park et al., 2016). It remains to be seen
whether or not there is a functional interaction between MYC
and Src in TNBC, and whether Src could be a mechanism of FAO
upregulation in MYC-driven TNBC, or vice versa. In addition,
as mentioned above, Terunuma et al. found elevation of acyl-
carnitines, the bottleneck intermediate of FAO, in ER-negative
human tumors compared to ER-positive or non-tumor tissue
(Terunuma et al., 2014), supporting our findings of dysregulated
FAO in TNBC (Camarda et al., 2016).
Although several studies have now indicated that MYC is
capable of dysregulating lipid metabolism, and in particular FAO,
no study has yet to validate a downstream mechanism by which
MYC activation dysregulates lipid metabolism and/or FAO in
vivo. It is worth noting that several potential mechanisms have
been described in vitro, including MYC-dependent induction
of mitochondrial biogenesis (Li et al., 2005), which has
been functionally linked to FAO in the context of MYC
inhibition (Zirath et al., 2013). In addition, there are several
other hypotheses supported by the literature that are worth
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noting. First, we found a marked downregulation in acetyl-
CoA carboxylase 2 (ACC2) protein expression in MYChigh,
but not MYClow PDXs, and it has been demonstrated that
downregulation of ACC2 in transgenic mice is sufficient to
upregulate FAO in vivo (Abu-Elheiga et al., 2001). Second, fatty
acid binding proteins (FABPs) are known to play a supporting
role in fatty acid oxidation as they are responsible for trafficking
fatty acids throughout the cell (Nieman et al., 2011). In ovarian
cancer that metastasizes to the omentum it was demonstrated
that FABP4 is upregulated in tumor cells and expressed in
omental adipocytes, and is necessary in both cell types to support
metastatic tumorigenesis (Nieman et al., 2011). Furthermore,
FABP5 has been found to be upregulated in TNBC, and is
associated with poor prognosis and recurrence-free survival in
TNBC (Liu et al., 2011). Thus, we postulate thatMYC reprograms
lipid metabolism in TNBCs via coordinated suppression of fatty
acid synthesis and upregulation of oxidation to support tumor
metabolic demands.
Finally, we and others recently described the necessity for PIM
kinase activity in MYC-overexpressing TNBC (Brasó-Maristany
et al., 2016; Horiuchi et al., 2016). PIM expression can promote
PGC1α expression, a master regulator of FAO (Beharry et al.,
2011). In addition, a recent study suggests that there may
be functional redundancy between PIM and PI3K in breast
cancer, and because PI3K is a known regulator of glycolysis,
PIM may then play a role in regulation of glycolysis in MYC-
overexpressing TNBC (Hu et al., 2016; Le et al., 2016). Further
studies are necessary to determine which, if any, of these potential
mechanisms are indeed at play in the regulation of FAO in
MYC-overexpressing TNBC.
In summary, MYC is capable of dysregulating lipid
metabolism in multiple cancer types, but a mechanism has
yet to described. Given that our work found that inhibition
of FAO is a therapeutic strategy against MYC-overexpressing
TNBC (Camarda et al., 2016), and a separate study found similar
results in a model of MYC-driven lymphoma (Pacilli et al.,
2013), it will be interesting to determine if this strategy could be
expanded to MYC-driven HB and/or HCC.
STUDIES OF PROTEIN AND NUCLEOTIDE
METABOLISM IN MYC-DRIVEN
LYMPHOMA
In addition to studies of lipid metabolism, the Eµ-MYC
model has also been used for studies of protein and nucleotide
metabolism. Eµ-MYC lymphomas display elevated protein
translation, a common of feature of many cancer types
(Barna et al., 2008). Barna et al. created a bi-allelic model
in which haploinsufficiency of the ribosomal protein RPL24
results in reduced protein translation back to non-tumor
levels. When this model was bred to the Eµ-MYC model
it resulted in decreased tumorigenesis (Barna et al., 2008).
With this model, the same lab recently utilized NMR-based
metabolomic analysis to profile changes in a number of metabolic
pathways in non-tumor lymphocytes, pre-tumor MYC-
driven lymphocytes, lymphocytes with reduced translation,
MYC-driven lymphocytes with normalized translation, and
tumorigenic MYC-driven lymphocytes. Cunningham et al.
found that the most notable translation-dependent difference
detected was a reduction in nucleotide-related metabolites,
specifically inosine monophosphate and adenosine mono-,
di-, and triphosphate. The authors then demonstrated that a
single enzyme, phosphoribosyl-pyrophosphate synthetase 2
(PRPS2), is responsible for increased nucleotide metabolism in
MYC-driven lymphoma via a cis-regulatory element in its 5′
UTR that is activated by translation initiation factor eIF4E, which
is itself hyperactivated in tumors. Additionally, MYC-driven
lymphomagenesis is at least in part dependent upon PRPS2
as Eµ-MYC crossed with PRPS2-null mice have a significant
delay in tumor initiation as well as a significant increase in
survival (Cunningham et al., 2014). Interestingly, elevated
protein synthesis in this model has also been linked to increased
activation of the unfolded protein response, which ultimately
promotes tumor cell survival via autophagy (Hart et al., 2012).
Thus, a combined increase in translation and autophagy may
contribute to MYC-driven metabolic adaptation in lymphomas.
REGULATION OF MYC BY METABOLISM
While MYC reprograms metabolism, there is also mounting
evidence of metabolic regulation of MYC in cancer and
tissue homeostasis. One notable example is the regulation of
MYC protein levels by HMG-CoA reductase, which has been
demonstrated in the Eµ-tTA/TRE-MYC model of lymphoma,
as well as the LT2-MYC model of liver cancer (Shachaf et al.,
2007; Cao et al., 2011). Mechanistically, HMG-CoA reductase
inhibition via atorvastatin reduced RAS and ERK1/2 signaling
in lymphoma, resulting in decreased ERK-dependent MYC
phosphorylation, and reduced MYC levels (Shachaf et al., 2007).
In liver cancer, however, atorvastatin was found to decrease MYC
phosphorylation and protein levels downstream of Rac GTPase
activity (Cao et al., 2011). The broader implication of this finding
is that a HMG-CoA reductase inhibitor such as atorvastatin
deserves further consideration in MYC-overexpressing tumor
types, and indeed atorvastatin did have anti-tumorigenic activity
in the aforementioned models of MYC-driven liver cancer
and lymphoma (Shachaf et al., 2007; Cao et al., 2011). A
second example is the regulation of MYC protein levels by the
enzyme O-linked N-acetylglucosamine transferase (OGT), which
catalyzes post-translational O-GlcNAcylation of proteins. This
phenomenon was demonstrated in a transgenic mouse model
of liver cancer with elevated OGT activity (Burén et al., 2016).
Interestingly, it has been previously demonstrated that MYC can
be glycosylated on threonine 58, a key regulatory residue that
is also phosphorylated, but the functional significance of this
modification remains to be elucidated (Chou et al., 1995).
STUDYING MYC AND METABOLISM IN
HUMAN PATIENTS
While transgenic and PDX mouse models are invaluable in
studying the role of MYC in cancer metabolism, the ultimate goal
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of these studies is to translate the findings from mouse models
to the clinic. The study of cancer metabolism in the clinic has
actually been a common practice for more than two decades
via the use of the glucose analog 18F-fluorodeoxyglucose (FDG;
Fletcher et al., 2008). Specifically, intravenous injection of 18F-
FDG coupled with positron emission tomography (PET) allows
for the imaging of a variety of tumor types, which preferentially
take up glucose to a higher degree than most non-tumor tissues
(Fletcher et al., 2008). Upregulation of hexokinase, which is very
likely a MYC transcriptional target in at least some tumor tissues
given it’s strong MYC-dependent regulation as discussed above
and elsewhere (Kim et al., 2007), results in phosphorylation and
trapping of the FDG probe in cancers (Fletcher et al., 2008).
Although 18F-FDG-PET imaging has generally been used to
detect tumors, recent advancements in our understanding of
the biology of tumorigenesis have led to much more specific
uses for 18F-FDG-PET. For example, Palaskas et al. reasoned
that a correlation between the expression of some mRNAs and
18F-FDG uptake may allow 18F-FDG-PET to identify the driver
oncogene(s) or oncogenic pathway(s) active in a patient’s tumor.
The authors integrated mRNA expression analysis and 18F-
FDG uptake from a panel of cancer cell lines and 18 patients
with breast cancer. Gene set enrichment analysis revealed a
number of upregulated molecular pathways in the cell lines and
patients with higher 18F-FDG uptake including, not surprisingly,
glycolysis. The authors then probed further for associations
between the 18F-FDG signature and breast cancer subtypes
and molecular drivers, and found that the 18F-FDG signature
correlated best with the TN/basal subtype and MYC-dependent
transcriptional activity. In addition, the authors retrospectively
stained biopsies from the 18 breast cancer patients, and found a
significant increase in MYC protein staining of the tumors with
high 18F-FDG uptake (Palaskas et al., 2011). To our knowledge,
further studies correlatingMYC expression with 18F-FDG uptake
in human tumors have not been conducted, but should be of
further consideration.
Although glucose uptake measurement via 18F-FDG-PET is
an invaluable clinical tool, some tumors are inherently 18F-FDG-
negative (Fletcher et al., 2008). Likewise, some non-tumor tissues
demonstrate high glucose ultilization (i.e., brain and liver),
making discernment of tumors via 18F-FDG-PET challenging.
Thus, alternative metabolites with high avidity for certain tumor
types are needed. To that end, preclinical studies have been
performed in the MTB-TOM MYC-driven breast cancer model
with 18F-(2S,4R)4-fluoroglutamine (Lieberman et al., 2011),
which could be useful in a number of MYC-driven tumors
that upregulate glutaminolysis as discussed above. In addition,
acetate was recently described by two studies as a critical carbon
fuel for a variety of primary tumors and tumors that have
metastasized to the brain (Comerford et al., 2014; Mashimo
et al., 2014). The critical acetate oxidation enzyme in cancer
appears to be the acetyl-CoA synthetase enzyme ACSS2, which
was found to be essential for tumorigenesis in a MYC-driven
model of liver cancer, and increased expression of ACSS2 was
associated with poor prognosis in TNBC (Comerford et al.,
2014). Notably, this study that focused on both primary brain
tumors and tumors that metastasized to the brain. Four patients
were infused with [1,2-13C]acetate during surgical resection of
their tumors. Post-operative NMR revealed de novo oxidation of
acetate to fuel the TCA cycle (Mashimo et al., 2014). Thus, acetate
deserves broader consideration as a bioenergetics substrate
in MYC-overexpressing tumors, both in terms of therapeutic
targeting and for imaging purposes. Finally, hyperpolarized 1-
13C-pyruvate MRSI has been used pre-clinically (Hu et al., 2011),
but has also been adopted for imaging of patient tumors as part
of a first-in-man clinical trial (Nelson et al., 2013). Indeed, there
is clear interest and opportunity for this modality to enter the
clinic, especially with expanded probes beyond 1-13C-pyruvate,
which so far has been the most well-studied (Kurhanewicz et al.,
2011).
Finally, it is worth taking note of several studies that focused
almost entirely on the analysis of clinical samples. Importantly,
these studies did not make a functional connection between the
metabolic phenotypes observed and MYC activity, even though
MYC has established functional roles in the cancer types studied.
For those interested, we refer to metabolic profiling performed
on primary tumors and serum samples from patients with HCC
(Huang et al., 2013; Liu et al., 2014), as well as breast cancer
(Cao et al., 2014; Kanaan et al., 2014; Cui et al., 2016). In
addition, integrated metabolomic and proteomic analysis has
been performed on primary RCC tumors (Wettersten et al.,
2015).
BROADER IMPLICATIONS
In this review, we have focused on the role of MYC in regulating
cancer metabolism in vivo. The majority of studies to date have
used transgenic mouse models or primary tumors. Thus, there
remains a tremendous amount of work to be done looking
outside the confines of the primary tumor to the role of MYC in
metastatic tumors, as well as cells within the microenvironment
and non-adjacent normal tissue, both of which will ultimately
have tremendous influence on which therapeutic strategies can
be translated to the clinic. With respect to metastasis, we
recently performed single-cell mRNA expression analysis on de
novo low- and high-burden metastases from orthotopic TNBC
PDXs and found that MYC expression was significantly elevated
in high-burden metastases (Lawson et al., 2015). Given that
cancer cell metabolism has been shown to change in metastasis
initiating cells (Pascual et al., 2016), when the metastatic cells
are in circulation (LeBleu et al., 2014), and depending on which
organ the metastatic tumor colonizes (Dupuy et al., 2015),
further studies will need to determine whether the reliance
on FAO, glucose, glutamine or other metabolites present in
primary MYC-overexpressing TNBC is maintained in high-
burden metastases.
Another aspect of the microenvironment that deserves
significant consideration is the immune cell component.
A recent study demonstrated that tumors with elevated
glucose consumption effectively drain glucose from the
microenvironment, resulting in decreased T-effector cell
function, which also relies upon glucose oxidation (Chang
et al., 2015). Notably, one of the effectors used in this study
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to promote glycolysis in a tumor line that would otherwise
succumb to T-effector surveillance was MYC (Chang et al.,
2015). Of course, T-effector cells are just one of a large number of
immune cell types present in the tumor microenvironment, and
the metabolic reliance of each of them could be effected by either
the tumor itself or therapies that specifically target metabolism.
The metabolism of other non-tumor cell types beyond the
immune compartment are also important to consider with
respect to MYC. Indeed, a recent study demonstrated that mice
heterozygous for MYC throughout their entire body are smaller,
live longer, and are more metabolically active (Hofmann et al.,
2015). Thus, targeting MYC-dependent metabolism in cancer
could likely impact MYC-dependent metabolism in non-tumor
cell types.
CONCLUSION
In summary, the role of MYC in the regulation of cancer
metabolism is as complex as the diverse functions of MYC itself.
What becomes clear after considering the multitude of studies
conducted is that the function of MYC, like other oncogenes such
as KRAS, is incredibly tissue-specific. However, while the overall
metabolic phenotype is usually tissue-specific, dysregulation of
individual metabolic pathways are often conserved across tissues,
and the combination of these considerations should inform
treatment decisions. Cancer research seeks to develop better and
potentially curative treatments for MYC driven tumors. Studies
of specific oncogene-driven transgenic cancer models allow for
discoveries of new metabolic pathways that are deregulated
in primary tumors, which could not be otherwise identified
in cultured cells. We anticipated that effectively translating
findings from studying cancer metabolism and its regulation by
oncogenes like MYC or KRAS to the clinic will be accelerated
through our understanding of how these oncogenes affect tissue
specific metabolism in vivo.
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